REG - Ergomed plc - Total Voting Rights <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

31/05/2016 16:45

RNS Number : 7911Z
Ergomed plc
31 May 2016
31 May 2016
Total Voting Rights and Issued Share Capital
In conformity with the FCA's Disclosure and Transparency Rules, Ergomed plc (the "Company") confirms that, as at the close of business on 31 May 2016, the Company's issued ordinary share capital consisted of 39,725,901 ordinary shares of 1 pence each in issue, all with voting rights. The Company holds no ordinary shares in treasury. 
Therefore, the total number of voting rights in the Company was 39,725,901 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
Stifel Nicolaus Europe Limited
Tel: +44 (0) 20 7710 7600
(Nominated Adviser and Joint Broker)
Jonathan Senior / Stewart Wallace 



Numis

(Joint Broker)
Michael Meade / James Black
Tel: +44 (0) 20 7260 1000


FTI Consulting
Tel: +44 (0) 20 3727 1000
Simon Conway / Mo Noonan

About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 80 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: http://ergomedplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
TVRABMATMBIJBJF